AU Patent

AU2022469157A1 — Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations

Assigned to Kadmon Corp LLC · Expires 2025-02-27 · 1y expired

What this patent protects

The present disclosure provides methods of administering belumosudil mesylate salt to certain subpopulations of patients with cGVHD.

USPTO Abstract

The present disclosure provides methods of administering belumosudil mesylate salt to certain subpopulations of patients with cGVHD.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022469157A1
Jurisdiction
AU
Classification
—
Expires
2025-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Kadmon Corp LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.